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COX-2 expression. Second, E2 potentiated BaP-induced nuclear fac-
tor-kB (NF-kB) activation, which regulates COX-2 expression. Third, 
although the aryl hydrocarbon receptor (AhR) did not play a role in 
BaP-induced COX-2 expression, the potentiation effect of E2 itself 
was AhR dependent. We further demonstrated that BaP induced the 
production of genotoxic E2 metabolites (2- and 4- hydroxyestradiols) 
via AhR-up-regulated cytochromes P450 1A1 and 1B1. These metabo-
lites could directly activate NF-kB to further promote COX-2 mRNA 
expression in human lung epithelial cells. These ﬁndings were further 
supported by increased PGE2 secretion in rat lung slice cultures. Our 
ﬁndings that the BaP-VE2 interaction enhanced COX-2 expression and 
hydroxyestradiol accumulation in the media of cultivated lung cells and 
tissues provide the needed scientiﬁc basis for higher risk of BaP-associ-
ated lung cancer in females.
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Small cell lung carcinoma (SCLC) is a highly metastatic disease with 
a poor prognosis due to its resistance to current modes of therapy. 
SCLC appears to arise from neuroendocrine cells with the potential 
to differentiate into a variety of lung epithelial cell lineages. In order 
to investigate molecular events underlying the cell type transition in 
SCLC, we established a differentiation cell model by modiﬁcation of a 
SCLC cell line H526 with a differentiation inducing agent 5-bromode-
oxyuridine (BrdU). The BrdU treatment led to a dramatic conversion 
from a suspension cell line H526 to an adherent cell line variant H526B 
exhibiting an epithelioid phenotype. DNA ﬁngerprinting by random 
ampliﬁed polymorphic DNA (RAPD) method showed an identical 
DNA binding pattern between H526 and H526B, indicating that the 
H526B subpopulation arose from the original cell line H526 and the 
contamination from other cell types can be ruled out. The BrdU modi-
ﬁed cells H526B remarkably reduced the ability of colony formation 
in soft agar and suppressed the tumor growth rate in immune-deﬁcient 
nude mice. The phenotypic transition was consistent with upregula-
tion of several lung cancer differentiation markers such as surfactant 
protein C (SFTPC), thyroid transcription factor 1 (TTF-1), Connexin 
26 (Cx26), insulin-like growth factor binding protein-related protein 
1 (IGFBP-rP1), as well as homeobox genes like LAGY, PITX1 and 
HOXB2. Our data suggest that BrdU induced cell differentiation could 
be linked to the development of a less aggressively phenotype in small 
cell lung cancer. 
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Transforming growth factor-β (TGF-β) is an essential regulator of cel-
lular physiological processes including proliferation, differentiation and 
angiogenesis. 
TGF-β signaling is mediated through a heterotetrameric cell-surface 
receptor complex of type II receptor (TβII) and type I receptor (TβRI); 
type I receptor. Type I receptor has 2 subtypes known as activin recep-
tor-like kinase 5 (ALK5: known as TβI) and activin receptor-like 
kinase 1 (ALK1). TβII/ALK5 complex activates Smad2/3 pathway and 
TβRII/ALK1 complex activates Smad 1/5 pathway. These pathways 
have been known to be associated with cellular growth inhibition 
through induction of phosphorylated Smad2; whereas cellular prolifera-
tion through induction of phosphorylated Sma1/5 in cancer cells.
Retinoids have been shown to possess differentiation, antiproliferative 
and apoptosis-inducing properties in cancer cells. 
We have studied the effects of all-trans retinoic acid (ATRA) after 
treated with different levels of TGF-β1 in non-small cell lung cancer 
cell lines (NSCLCs). In addition, we examed whether ATRA effects in 
signal pathway of NSCLCs.
We analyzed expression of TGF-β receptor I and II (TGF-β I, TGF-β 
RII) by RT-PCR and treated with ATRA and a variety of concentrations 
of TGF-β1 for different durations in NSCLCs. In addition, the time-de-
pendent cytotoxic effects of ATRA alone, TGF-β1 alone and combina-
tion were studied by the MTT and cell counting assays. We carried out 
western blot analysis to evaluate whether combined treatment affects 
the expression of Smads or TGF-β RI (ALK5, ALK1). Finally, we car-
ried out migration assay to evaluate whether the combined treatment of 
ATRA and TGF-β1 affects the migration of NSCLCs.
The results showed that TGF-β1 alone increased cellular growth of 
NSCLCs, and the combined treatment of ATRA and TGF-β1 inhibited 
the growth of NSCLCs. The combined treatment of ATRA and TGF-
β1 reduced TGF-β1-induced phosphorylated Smad1/5/8. However, 
the total protein levels of ALK5 and ALK1 were not changed by the 
combined treatment of ATRA and TGF-β1. In addition, the combined 
treatment of ATRA and TGF-β1 reduced migration compared to the 
treatment with TGF-β1 in A549 and H1299 cell lines. 
Therefore, these ﬁndings suggest that treatment with ATRA reduced 
the growth and migration of NSCLCs by inhibition of TGF-β1-induced 
phosphorylated-Smad1/5/8 which caused growth progression and 
migration. ATRA may have a potential therapeutic role in the treatment 
of lung cancer patients with increased levels of TGF-β1.
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